SU1731064A3 - Способ получени пиримидиновых нуклеозидов - Google Patents

Способ получени пиримидиновых нуклеозидов Download PDF

Info

Publication number
SU1731064A3
SU1731064A3 SU874355176A SU4355176A SU1731064A3 SU 1731064 A3 SU1731064 A3 SU 1731064A3 SU 874355176 A SU874355176 A SU 874355176A SU 4355176 A SU4355176 A SU 4355176A SU 1731064 A3 SU1731064 A3 SU 1731064A3
Authority
SU
USSR - Soviet Union
Prior art keywords
alkyl
hydroxy
hydrogen
oxo
herpes
Prior art date
Application number
SU874355176A
Other languages
English (en)
Russian (ru)
Inventor
Джордж Рахим Саад
Джейн Мартин Пьюрифой Дороти
Original Assignee
Дзе Велкам Фаундейшн, Лимитед (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Велкам Фаундейшн, Лимитед (Фирма) filed Critical Дзе Велкам Фаундейшн, Лимитед (Фирма)
Application granted granted Critical
Publication of SU1731064A3 publication Critical patent/SU1731064A3/ru
Priority to LV920338A priority Critical patent/LV5273A3/xx
Priority to LTRP271A priority patent/LT2064B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Silicon Polymers (AREA)
SU874355176A 1986-12-15 1987-12-14 Способ получени пиримидиновых нуклеозидов SU1731064A3 (ru)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LV920338A LV5273A3 (lv) 1986-12-15 1992-12-18 Panemiens pirimidinnukleozidu iegusanai
LTRP271A LT2064B (lt) 1986-12-15 1992-12-30 Pirimidininiu nukleozidu gavimo budas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds

Publications (1)

Publication Number Publication Date
SU1731064A3 true SU1731064A3 (ru) 1992-04-30

Family

ID=10609013

Family Applications (1)

Application Number Title Priority Date Filing Date
SU874355176A SU1731064A3 (ru) 1986-12-15 1987-12-14 Способ получени пиримидиновых нуклеозидов

Country Status (30)

Country Link
US (1) US5079235A (enExample)
EP (3) EP0272065B1 (enExample)
JP (2) JPS63165397A (enExample)
KR (1) KR880007521A (enExample)
CN (2) CN87108265A (enExample)
AT (1) ATE88713T1 (enExample)
AU (2) AU601529B2 (enExample)
CA (1) CA1319143C (enExample)
CS (3) CS275402B6 (enExample)
DD (2) DD274766A5 (enExample)
DE (1) DE3785651T2 (enExample)
DK (2) DK654287A (enExample)
ES (1) ES2054693T3 (enExample)
FI (2) FI941523L (enExample)
GB (1) GB8629892D0 (enExample)
HU (4) HU200932B (enExample)
IE (2) IE930471L (enExample)
IL (3) IL95141A (enExample)
LT (1) LT2064B (enExample)
LV (1) LV5273A3 (enExample)
MC (1) MC1882A1 (enExample)
MX (1) MX9203216A (enExample)
NO (1) NO167576C (enExample)
NZ (1) NZ222898A (enExample)
PH (2) PH24104A (enExample)
PL (3) PL160321B1 (enExample)
PT (1) PT86356B (enExample)
RU (1) RU2036199C1 (enExample)
SU (1) SU1731064A3 (enExample)
ZA (1) ZA879382B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2300381C2 (ru) * 1998-08-10 2007-06-10 Айденикс (Кайман) Лимитед β-L-2'-ДЕЗОКСИНУКЛЕОЗИДЫ ДЛЯ ЛЕЧЕНИЯ ГЕПАТИТА В

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366685B1 (en) * 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
ATE161722T1 (de) 1990-07-19 1998-01-15 Wellcome Found Enzyminaktivatoren
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
EP0637965B1 (en) * 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
WO1993024506A1 (en) * 1992-05-26 1993-12-09 Alberta Research Council IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWISC AND LacNAc COMPOUNDS
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
ES2206522T3 (es) * 1994-12-13 2004-05-16 Taiho Pharmaceutical Co., Ltd. Derivados de nucleosido sustituidos en 3'.
WO1997023230A1 (en) * 1995-12-22 1997-07-03 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
EP0878193A1 (en) * 1996-02-02 1998-11-18 Showa Shell Sekiyu K.K. Remedies for herpesvirus infection caused by herpesvirus and preventives for recurrence of the infection both containing triterpene derivatives as the active ingredient
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
EP1569658A4 (en) 2001-12-20 2007-05-30 Pharmassett Ltd TREATMENT OF EBV AND KHSV INFECTION AND AN ASSOCIATED ABNORMAL CELL PROLIFERATION
CN102441170A (zh) 2004-12-03 2012-05-09 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法
LT2757091T (lt) 2008-04-01 2017-09-11 Biosearch Technologies, Inc. Stabilizuotos nukleorūgšties tamsūs kvenčerio-fluoroforo zondai
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
EP2488182B1 (en) 2009-10-14 2017-07-19 Elion Oncology LLC Treating neurotoxicity associated with combinations of 5-FU or its prodrugs and DPD inhibitors
US9598456B2 (en) * 2014-03-30 2017-03-21 Cepheid Modified cytosine polynucleotide oligomers and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) * 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Патент ЕР № 0180897, кл. С07Н 19/073, 14.05.86. Патент US Ms 4599404, «л. С07Н 19/073,08.07.86. Патент GB № 1601020, кл. С07Н 19/073, 1978. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2300381C2 (ru) * 1998-08-10 2007-06-10 Айденикс (Кайман) Лимитед β-L-2'-ДЕЗОКСИНУКЛЕОЗИДЫ ДЛЯ ЛЕЧЕНИЯ ГЕПАТИТА В

Also Published As

Publication number Publication date
CS275398B2 (en) 1992-02-19
PH24104A (en) 1990-03-05
LV5273A3 (lv) 1993-10-10
RU2036199C1 (ru) 1995-05-27
GB8629892D0 (en) 1987-01-28
NO875209L (no) 1988-06-16
MC1882A1 (fr) 1989-01-24
FI941523A0 (fi) 1994-03-31
PL269462A1 (en) 1989-06-26
HUT46336A (en) 1988-10-28
IE930470L (en) 1988-06-15
ES2054693T3 (es) 1994-08-16
DK654287D0 (da) 1987-12-14
AU626041B2 (en) 1992-07-23
HU199867B (en) 1990-03-28
FI875487A7 (fi) 1988-06-16
EP0486477A3 (en) 1992-06-17
PL160322B1 (pl) 1993-02-26
NO167576B (no) 1991-08-12
DE3785651D1 (de) 1993-06-03
CS342591A3 (en) 1992-04-15
DK654287A (da) 1988-06-16
LT2064B (lt) 1993-06-15
HU207735B (en) 1993-05-28
JPH0378370B2 (enExample) 1991-12-13
HU903829D0 (en) 1990-11-28
FI941523A7 (fi) 1994-03-31
IL95141A0 (en) 1991-06-10
CN1080292A (zh) 1994-01-05
US5079235A (en) 1992-01-07
HU202112B (en) 1991-02-28
EP0486477A2 (en) 1992-05-20
DD264924A5 (de) 1989-02-15
NO167576C (no) 1991-11-20
ZA879382B (en) 1989-08-30
AU601529B2 (en) 1990-09-13
CS767588A3 (en) 1991-02-12
CN87108265A (zh) 1988-07-13
EP0272065B1 (en) 1993-04-28
PT86356B (pt) 1990-11-07
EP0417560A1 (en) 1991-03-20
IL84810A0 (en) 1988-06-30
CA1319143C (en) 1993-06-15
IE930471L (en) 1988-06-15
DK169991A (da) 1991-10-04
FI875487A0 (fi) 1987-12-14
PL277926A1 (en) 1989-08-21
PH24870A (en) 1990-12-26
HU200932B (en) 1990-09-28
EP0272065A2 (en) 1988-06-22
JPH03141292A (ja) 1991-06-17
IL95141A (en) 1992-05-25
FI941523L (fi) 1994-03-31
MX9203216A (es) 1992-07-01
PL158050B1 (pl) 1992-07-31
DK169991D0 (da) 1991-10-04
NO875209D0 (no) 1987-12-14
KR880007521A (ko) 1988-08-27
PT86356A (en) 1988-01-01
NZ222898A (en) 1990-12-21
JPS63165397A (ja) 1988-07-08
DD274766A5 (de) 1990-01-03
DK168323B1 (da) 1994-03-14
DE3785651T2 (de) 1993-11-11
CS275402B6 (en) 1992-02-19
ATE88713T1 (de) 1993-05-15
AU8252187A (en) 1988-06-16
EP0272065A3 (en) 1988-11-17
PL277927A1 (en) 1989-08-21
IL84810A (en) 1992-05-25
AU5989090A (en) 1990-11-08
PL160321B1 (pl) 1993-02-26
CS916187A2 (en) 1991-02-12

Similar Documents

Publication Publication Date Title
EP0049072B1 (en) Guanine compounds and their use for the preparation of anti-viral agents
Chiang et al. Adenosylhomocysteine hydrolase inhibitors: synthesis of 5′-deoxy-5′-(isobutylthio)-3-deazaadenosine and its effect on Rous sarcoma virus and Gross murine leukemia virus
US5962684A (en) Method of preparation of dideoxycarbocyclic nucleosides
US4247544A (en) C-5 Substituted uracil nucleosides
US4093714A (en) 9β-D-Arabinofuranosylpurine nucleotides and method of use
US4386076A (en) (E)-5-(2-Halogenovinyl)-arabinofuranosyluracil, process for preparation thereof, and uses thereof
PL158050B1 (pl) Sposób wytwarzania 5-podstawionych nukleozydów pirymidynowych PL PL
US4931559A (en) Optically-active isomers of dideoxycarbocyclic nucleosides
US3472838A (en) 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
DE2047368A1 (de) Verfahren zur Herstellung von 9 (beta D Arabinofuranosyl) adenin 5 phos phat
US3870700A (en) 2-halogeno-2-deoxy-5-(substituted)uridines
Cristalli et al. Adenosine deaminase inhibitors. Synthesis and biological activities of deaza analogs of erythro-9-(2-hydroxy-3-nonyl) adenine
Salvatori et al. Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1
RU2111970C1 (ru) 3'-оксимино-2',3'-дидезоксинуклеозиды
Lin et al. Synthesis and biological activities of 5-trifluoromethyl-5'-azido-2', 5'-dideoxyuridine and 5-trifluoromethyl-5'-amino-2', 5'-dideoxyuridine
Chen et al. Boronic acid derivatives targeting HIV-1
GB1156021A (en) Ribofuranosyl Deazapurine Cyclic Phosphates
Hall Riboside Derivatives of 6-Methyl-asym-triazine-3, 5 (2, 4)-dione1
Mikhailov et al. Use of cyclohexene epoxides in the preparation of carbocyclic nucleosides
Earl et al. Chemical investigations of citraconimide
CH632748A5 (de) Verfahren zur herstellung von uracilderivaten.
Kwong et al. Synthesis and antiviral evaluation of analogs of adenosine-N 1-oxide and 1-(benzyloxy) adenosine
GB2211185A (en) Uridine derivatives and antiviral agents containing them
DE2537294C3 (de) S-Inosyl-L-cystein und Verfahren zu seiner Herstellung
IE51332B1 (en) Novel adenine nucleoside derivatives,their preparation and pharmaceutical compositions containing them